|04-02-2012, 10:07 AM||#1|
Join Date: Nov 2004
Acorda Therapeutics Launches New Interactive Website Spotlighting Treatment with Ampy
Acorda Therapeutics Launches New Interactive Website Spotlighting Treatment with Ampyra® (Dalfampridine) of Walking Problems in Patients with Multiple Sclerosis
New site – www.AmpyraJourneys.com – is first to focus exclusively on walking problems for people living with MS, with patient profiles, medical information, and opportunities for visitors to post messages of inspiration to help others.
HAWTHORNE, N.Y.--(BUSINESS WIRE)--
Acorda Therapeutics, Inc. (Nasdaq: ACOR - News) today announced the launch of a new interactive patient website called Ampyra Journeys (www.AmpyraJourneys.com). The site is the first-ever stand-alone patient site to focus on walking problems associated with multiple sclerosis (MS). Ampyra (dalfampridine) is an oral medication approved by the FDA as a treatment to improve walking in patients with multiple sclerosis. This was demonstrated by an increase in walking speed.
|Thread||Thread Starter||Forum||Replies||Last Post|
|Acorda Therapeutics Licenses Rights to Investigational Treatment for Spinal Cord Inju||manouli||Cure||3||07-01-2011 10:28 PM|
|Acorda Therapeutics Launches ZANAFLEX CAPSULES for the Management of Spasticity in People||Jeremy||Cure||0||04-04-2005 07:33 AM|
|BW)(NY-ACORDA) Acorda Therapeutics Completes $55 Million Private Financing Led By Easton Hunt Capital Partners, L.P.||Max||Funding, Legislation, & Advocacy||2||05-13-2003 10:10 AM|
|BW)(NY-ACORDA-THERAPEUTICS) Acorda Therapeutics to Present at the SG Cowen 23rd Annual Healthcare Conference||Max||Cure||0||03-19-2003 11:34 AM|
|Acorda Therapeutics||Birde||Web Links||0||07-29-2001 07:48 PM|